Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime–sulbactam vs cefoperazone–sulbactam for moderate to severe acute bacterial respiratory or urinary infections
CTR20131026Phase 2Active
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Oct 2013
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of ceftazidime + sulbactam in acute bacterial respiratory infection (ABRI), Acute Bacterial Urinary Tract Infection (UTI), bacterial disease, Ceftazidime-resistant bacterial infection, sponsored by Xiangbei Welman Pharmaceuticals. Started Oct 2013; status: active.
02
Drugs
ceftazidime + sulbactam
03
Conditions
acute bacterial respiratory infection (ABRI)Acute Bacterial Urinary Tract Infection (UTI)bacterial diseaseCeftazidime-resistant bacterial infection
Beyond the preview
Go deeper on CTR20131026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131026.